Brief Title
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
Official Title
Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Brief Summary
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
objective response rate
Secondary Outcome
number of patients with adverse events
Condition
Nasopharyngeal Cancer
Intervention
Docetaxel, Cisplatin
Study Arms / Comparison Groups
weekly docetaxel and cisplatin
Description: Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
51
Start Date
July 2006
Primary Completion Date
May 2011
Eligibility Criteria
Inclusion Criteria: - histologically confirmed nasopharyngeal cancer - chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment) - ECOG 0-1 - at least one measurable lesion Exclusion Criteria: - other cancer - pregnat - docetaxel hypersentitivity history - severe heart or pulmonary disease
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, 82-2-3410-3459, [email protected]
Location Countries
Korea, Republic of
Location Countries
Korea, Republic of
Administrative Informations
NCT ID
NCT01312311
Organization ID
2006-07-005
Study Sponsor
Samsung Medical Center
Study Sponsor
, ,
Verification Date
March 2011